Vironexis has developed a pipeline of over ten product candidates using its TransJoin AAV Gene Therapy Platform, targeting blood-based cancers, solid tumor metastasis, and a cancer vaccine.
Differentiators of CD19-Targeted Therapies CAR-T TransJoin Off-the-shelf No Yes Single dose Yes Yes Long-term efficacy (months to years) Yes Yes Involves all T cells No Yes Recruits freshly made T cells from bone marrow No Yes Highly efficient T cell signaling (via the mature T cell receptor) No Yes Risk of manufacturing failure Yes No […]
The SENTRY-CD19 trial shows MRD-negative complete responses in three anti-AAV antibody-naïve patients with relapsed/refractory acute lymphoblastic leukemia after a single dose of VNX-101, with durable responses observed.
Vironexis Biotherapeutics launched its TransJoin AAV Gene Therapy Platform and announced a pipeline of over ten candidates for blood-based cancers, solid tumor metastasis prevention, and a cancer vaccine.
Vironexis combines expertise in oncology research and gene therapy to develop In-Vivo Protein Engineering delivered T-cell Immunotherapy for cancer treatment.
